Clinical Trial Update: Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1 neoadjuvant trial of in-situ REIC/Dkk-3 for prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• REIC/Dkk-3 (in-situ) (REIC/Dkk-3)

Snippet

Sponsor: Momotaro-Gene Inc. | Conditions: Prostate Cancer | Phase 1 | Status: WITHDRAWN